Intellia Therapeutics, Inc.
NTLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,152,579 | $2,706,597 | $2,685,553 | $8,382,507 |
| - Cash | $189,182 | $226,748 | $523,506 | $123,406 |
| + Debt | $210,198 | $115,346 | $130,703 | $74,023 |
| Enterprise Value | $1,173,595 | $2,595,195 | $2,292,750 | $8,333,124 |
| Revenue | $57,877 | $36,275 | $52,121 | $33,053 |
| % Growth | 59.6% | -30.4% | 57.7% | – |
| Gross Profit | $47,592 | $27,299 | $44,549 | $26,162 |
| % Margin | 82.2% | 75.3% | 85.5% | 79.2% |
| EBITDA | -$523,978 | -$506,315 | -$450,592 | -$260,959 |
| % Margin | -905.3% | -1,395.8% | -864.5% | -789.5% |
| Net Income | -$519,021 | -$481,192 | -$474,186 | -$267,892 |
| % Margin | -896.8% | -1,326.5% | -909.8% | -810.5% |
| EPS Diluted | -5.25 | -5.42 | -6.16 | -3.78 |
| % Growth | 3.1% | 12% | -63% | – |
| Operating Cash Flow | -$348,880 | -$394,086 | -$333,287 | -$225,030 |
| Capital Expenditures | -$5,778 | -$13,985 | -$58,390 | -$12,756 |
| Free Cash Flow | -$354,658 | -$408,071 | -$391,677 | -$237,786 |